Emestop (ramosetron hydrochloride) / Samyang Group - LARVOL DELTA

Hange-Shashin-to Suppresses Serotonin-Induced Neurogenic Intestinal Contraction via Inhibition of 5-HT3A Receptor Signaling. (PubMed, Cell Physiol Biochem) - "HST suppresses 5-HT-induced neuronal excitation through inhibition of 5-HT3A receptor-mediated ion channel activity, resulting in reduced downstream intestinal motor responses. These findings identify the 5-HT3A receptor as a molecular target of HST and provide mechanistic insight into its pharmacological actions on 5-HT-mediated intestinal dysfunction."

Journal • Gastroenterology • Gastrointestinal Disorder

A Scoping Review of 5-HT3 Antagonist Antiemetic Medication Safety in the Management of Nausea and Vomiting of Pregnancy. (PubMed, Pharmacoepidemiol Drug Saf) - "Ondansetron likely poses low risk of harm to maternal and neonatal health, especially considering the excess risks of untreated NVP; however additional research is required for certain congenital anomalies. Further investigation is also warranted into granisetron safety before its widespread use during pregnancy."

Journal • Review • Novel Coronavirus Disease

Efficacy of Combined Ramosetron and Dexamethasone on Postoperative Recovery in Patients Undergoing General Anesthesia: A Multicenter Randomized Controlled Trial. (PubMed, J Clin Med) - " Low-dose dexamethasone to ramosetron substantially reduced postoperative nausea and improved analgesic profiles at 6 h in patients managed without PCA. However, no significant between-group differences were observed at 24 h."

Clinical • Journal • Anesthesia • Orthopedics • Otorhinolaryngology • Pain

Effect of Opioid-Sparing Anesthesia on Postoperative Nausea and Vomiting After Breast Surgery: A Single-Center Randomized Controlled Trial. (PubMed, J Clin Med) - " Adult women undergoing elective breast surgery were randomized 1:1 to opioid-sparing anesthesia with dexmedetomidine and lidocaine or conventional opioid-based anesthesia with remifentanil...All patients received standardized sevoflurane anesthesia, dexamethasone, ramosetron, quantitative neuromuscular monitoring, and postoperative fentanyl patient-controlled analgesia...Trial Registration: Clinical Research Information Service (CRIS), KCT0009829. Registered on 10 October 2024."

Journal • Anesthesia • Pain

Comparative Effectiveness of Hangeshashinto and Ramosetron for the Treatment of Irritable Bowel Syndrome with Diarrhea. (PubMed, Digestion) - "CONCLUSION In this exploratory real-world analysis, hangeshashinto showed short-term symptom improvement comparable to ramosetron, and adding hangeshashinto to ramosetron was associated with lower follow-up symptom scores than ramosetron monotherapy. Prospective studies are warranted to confirm comparative effectiveness and identify patients most likely to benefit."

HEOR • Journal • Gastrointestinal Disorder

Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndrome (clinicaltrials.gov) - P4 | N=76 | Not yet recruiting | Sponsor: Md. Aminul Islam

New P4 trial • Gastrointestinal Disorder

Ramosetron-induced acute dystonic extrapyramidal reactions: A case report. (PubMed, Saudi J Anaesth) - "Extrapyramidal symptoms induced by ondansetron, a selective 5-HT3 receptor antagonist, are well-documented. The symptoms promptly resolved after the administration of intravenous benzodiazepine. This case highlights the importance of recognizing and managing uncommon extrapyramidal motor disturbances associated with ramosetron use."

Journal • Anesthesia • CNS Disorders • Epilepsy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT3 Receptor Antagonists: 2026 Update. (PubMed, Clin Pharmacol Ther) - "Most of the 5-HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent of CYP2D6 involvement varies. This guideline is an update to the 2016 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron and includes updated information on CYP2D6 genetic testing and evidence tables. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT3 receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457)."

Biomarker • Journal

Prophylactic Effectiveness of Ramosetron versus Ondansetron for Preventing Postoperative Nausea and Vomiting in Adults: A Randomized Comparative Study. (PubMed, Ann Afr Med) - "Ramosetron provides superior prophylactic effectiveness against postoperative nausea and vomiting compared to ondansetron, particularly during the early recovery phase, while maintaining equivalent tolerability."

Journal • Anesthesia

Comparative efficacy of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists with or without dexamethasone for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy (HEC): a network meta-analysis. (PubMed, PeerJ) - "Palonosetron + Dexamethasone demonstrates superior efficacy over Ondansetron + Dexamethasone or Granisetron + Dexamethasone, particularly in the delayed phase. Further studies are needed between Palonosetron + Dexamethasone and Tropisetron + Dexamethasone or Ramosetron + Dexamethasone, as well as between Palonosetron monotherapy and 1st 5-HT3 antagonists + Dexamethasone."

CINV • Clinical • Journal • Retrospective data • Chemotherapy-Induced Nausea and Vomiting

Prevention of Pain on Propofol Injection: A Comparison of Pretreatment with 5-Hydroxytryptamine 3 Antagonists Granisetron, Ondansetron, and Ramosetron. (PubMed, Ann Afr Med) - "Granisetron is the most effective in reducing PIP, though ondansetron and ramosetron also offer significant pain relief."

Journal • Anesthesia • Pain

Accidental epidural administration of sugammadex and ramosetron - A case report. (PubMed, Anesth Pain Med (Seoul)) - "Although the outcome was benign, this incident underscores the potential risks of wrong-route drug delivery and highlights the need for vigilance and preventive strategies in perioperative medication management."

Journal • Anesthesia

Effects of Esketamine Combined with Butorphanol Tartrate for Postoperative Analgesia on Postoperative Nausea and Vomiting in Female Patients After Thoracic Surgery. (ChiCTR) - P=N/A | N=150 | Not yet recruiting | Sponsor: The Second Hospital of Dalian Medical University; The Second hospital of Dalian Medical University

New trial • Lung Cancer • Oncology • Solid Tumor

Comparison of Ondansetron and Cyclizine for the Management of Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis. (PubMed, Cureus) - "Due to its cost-effectiveness and potential specific benefit in diagnostic laparoscopy, it might be useful for ambulatory surgical centres aiming to optimize value-based care. However, the efficacy of cyclizine within modern multimodal protocols has not been consistently determined by these monotherapy trials, and long-term assessments of combined antiemetic strategies need to be evaluated."

Journal • Retrospective data • Review • Anesthesia

Continuous Transversus Abdominis Plane Block After Laparoscopic Sleeve Gastrectomy in 50 Consecutive Cases. (PubMed, J Metab Bariatr Surg) - "There was no significant difference between the 2 groups in postoperative NRS scores at 1 and 6 hours, incidence of nausea or vomiting, injection of acetaminophen, non-steroidal anti-inflammatory drugs, or metoclopramide within 24 or 48 hours, injection of opioid or ramosetron within 48 hours. There were 2 cases of complications related to continuous TAP block where there was difficulty in removing the catheters and needed to be removed under local anesthesia. Although continuous TAP block did not reduce cumulative opioid consumption, the need for additional opioid and antiemetic injection can be reduced within the postoperative 24 hours."

Journal • Anesthesia • Cardiovascular • Diabetes • Dyslipidemia • Gastrointestinal Disorder • Hypertension • Metabolic Disorders • Obstructive Sleep Apnea • Pain • Respiratory Diseases • Sleep Disorder

Effectiveness of a 5-Hydroxytryptamine Type 3 Receptor Antagonist for Treating Nintedanib-Induced Diarrhea: A Prospective Observational Study. (PubMed, J Clin Med) - " Between October 2022 and March 2025, we enrolled patients with severe nintedanib-induced diarrhea that was uncontrolled by loperamide and/or probiotics. No prominent adverse events were associated with ramosetron administration. Ramosetron, a 5-HT3 antagonist, improved stool frequency and stool form in patients with severe nintedanib-induced diarrhea."

Journal • Observational data • Fibrosis • Gastrointestinal Disorder • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

The Safety and Efficacy of Ramosetron versus Psyllium for the Treatment of Fecal Incontinence (SERAFI): Study protocol for a randomized, parallel, non-inferiority trial. (PubMed, Trials) - P2/3 | "It is believed that 5-HT3 receptor antagonists, along with Psyllium, can improve bowel habits and alleviate symptoms, thereby enhancing the quality of life for patients with FI."

Head-to-Head • Journal • Constipation

Palonosetron, a 5-HT3 Receptor Antagonist, Induces G1 Cell Cycle Arrest and Autophagy in Gastric Cancer Cells. (PubMed, Int J Mol Sci) - "This study aimed to evaluate the effect of 5-HT3 receptor antagonists (ondansetron, palonosetron, and ramosetron) on cancer cell growth using AGS and MKN-1 cell lines, as well as the xenograft mouse model. These findings suggest that 5-HT3 receptor antagonists, especially palonosetron, exert anti-tumor effects in gastric cancer through G1 cell cycle regulation and immunomodulation. The results position palonosetron as a promising lead for further preclinical development in gastric cancer."

Journal • Gastric Cancer • Immunology • Oncology • Solid Tumor • IL1B • IL6 • TNFA • TP53

Pharmacotherapy for fecal incontinence: potential treatment with a traditional Japanese medicine Kampo. (PubMed, Ann Coloproctol) - "Strongly recommended treatments include the antidiarrheal agent loperamide and stool bulking or solidifying agents, such as dietary fiber and polycarbophil. Other therapeutic options include ramosetron, a 5-HT3 receptor antagonist; amitriptyline, a tricyclic antidepressant; and sodium valproate and diazepam, which are GABAergic neuromodulators. Recently, research has explored the efficacy and mechanism of action of DKT, a traditional Japanese medicine Kampo. Historically used for abdominal symptoms like bloating and known for promoting intestinal motility, emerging evidence suggests DKT may also effectively manage FI."

Journal • Review

Ramosetron as a Supportive Agent to Continue Nintedanib in Patients with Interstitial Lung Disease. (PubMed, Intern Med) - "The selective use of ramosetron may improve adherence to nintedanib treatment. However, prospective studies are required to validate these findings."

Journal • Gastrointestinal Disorder • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Efficacy of intraoperative low-dose remimazolam as a third antiemetic agent for preventing early postoperative nausea in high-risk patient: A Randomized controlled trial. (PubMed, BMC Anesthesiol) - P=N/A | "Low-dose remimazolam infusion did not reduce the incidence of PONV at postoperative 24 h. It was associated with a lower incidence of nausea at postoperative 6 h and dizziness in the PACU."

Clinical • Journal • Anesthesia • Pain

The effects of oxycodone and sufentanil postoperative analgesia on postoperative delirium after thoracoscopic lobectomy: a prospective, randomized controlled study (ChiCTR) - P4 | N=148 | Recruiting | Sponsor: Jianyang People's Hospital; Jianyang People's Hospital

New P4 trial • CNS Disorders

Protective Effect of Palonosetron against Cisplatin-Induced Cytotoxicity via Decreased Phosphorylation of p38. (PubMed, Biol Pharm Bull) - "Recently, we demonstrated that the incidence of CDDP-induced nephrotoxicity was significantly lower in patients receiving palonosetron, a 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA), than in those receiving other 5-HT3RAs (ondansetron, ramosetron, and granisetron). Thus, these findings suggest that concomitant treatment with palonosetron reduces CDDP-induced cytotoxicity by inhibiting p38 phosphorylation, but does not inhibit the hOCT2-mediated transport of CDDP. The present findings provide novel insights into the reduction of CDDP-induced cytotoxicity through concomitant palonosetron treatment."

Journal

Effect of esketamine on sleep quality in elderly patients undergoing knee arthroplasty surgery (ChiCTR) - P4 | N=66 | Completed | Sponsor: The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University

New P4 trial • CNS Disorders • Orthopedics • Sleep Disorder

Comparison of ramosetron with different doses on hemodynamic influences during total intravenous anesthesia induction with propofol and remifentanil and endotracheal intubation (Euroanaesthesia 2025) - "We recorded hemodynamics [systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), and heart rate (HR)], before injecting either ramosetron or normal saline, at loss of consciousness, at 1 min after rocuronium injection, before endotracheal intubation, and 1 min after endotracheal intubation. A high dose of ramosetron can be expected to reduce the degree of blood pressure drop that occurs during anesthesia induction and endotracheal intubation. However, further studies are needed on whether a high dose of ramosetron can satisfy the effectiveness of preventing PONV or drug injection pain simultaneously without clinically significant side effects."

Intubation • Anesthesia • Hypotension • Pain